Will GoodRX Stock Bounce Back?
GoodRX (NASDAQ:GDRX) tracks prescription drug prices and its model was…
Sell
39
BHST Quote, Financials, Valuation and Earnings
Last price:
$7.0500
Seasonality move
:
-10.86%
Day range:
$6.9093 - $7.1767
52-week range:
$4.6600 - $7.8600
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
4.26x
P/B ratio:
84.68x
Volume:
3.5K
Avg. volume:
9.1K
1-year change:
16.51%
Market cap:
$119.7M
Revenue:
$25.2M
EPS (TTM):
-$0.50
Analysts' Opinion
-
Consensus RatingBioHarvest Sciences has received a consensus rating of Buy. The company's average rating is a Buy based on 1 Buy rating, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $14.7500, BioHarvest Sciences has an estimated upside of 113.48% from its current price of $6.9093.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $12.0000 representing 100% downside risk from its current price of $6.9093.
Fair Value
-
According to the consensus of 1 analyst, BioHarvest Sciences has 113.48% upside to fair value with a price target of $14.7500 per share.
BHST vs. S&P 500
-
Over the past 5 trading days, BioHarvest Sciences has underperformed the S&P 500 by -4.88% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
BioHarvest Sciences does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
BioHarvest Sciences has grown year-over-year revenues for 0 quarters straight. In the most recent quarter BioHarvest Sciences reported revenues of $7.9M.
Earnings Growth
-
BioHarvest Sciences has grown year-over-year earnings for 1 quarter straight. In the most recent quarter BioHarvest Sciences reported earnings per share of -$0.13.
Enterprise value:
123.8M
EV / Invested capital:
--
Price / LTM sales:
4.26x
EV / EBIT:
--
EV / Revenue:
4.47x
PEG ratio (5yr expected):
-0.02x
EV / Free cash flow:
-12.60x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$15.5M
Return On Assets:
-36.94%
Net Income Margin (TTM):
-31.3%
Return On Equity:
-534.46%
Return On Invested Capital:
-145.22%
Operating Margin:
-21.87%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | $7M | $15.9M | $27.7M | $5.3M | $7.9M | |
| Gross Profit | $1.8M | $7.8M | $15.5M | $3M | $4.6M | |
| Operating Income | -$10.5M | -$8.9M | -$7.3M | -$1.4M | -$1.7M | |
| EBITDA | -$7.7M | -$10.6M | -$5.5M | -$1.2M | -$1.3M | |
| Diluted EPS | -$0.76 | -$1.35 | -$0.50 | -$0.48 | -$0.13 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $6.6M | $3.3M | $3.2M | $7.6M | $9.6M | |
| Total Assets | $9.9M | $8M | $8.5M | $12.9M | $26.6M | |
| Current Liabilities | $7M | $2.3M | $10M | $13.3M | $18.9M | |
| Total Liabilities | $12.7M | $6.7M | $13.6M | $16.1M | $27.5M | |
| Total Equity | -$2.8M | $1.3M | -$5.2M | -$3.2M | -$876K | |
| Total Debt | -- | -- | $6.1M | $8M | $7.5M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$8.4M | -$8.4M | -$6.5M | -$1.6M | -$1.4M | |
| Cash From Investing | -$1.2M | -$1.3M | -$3.5M | -$222K | -$680K | |
| Cash From Financing | $8.7M | $12.8M | $10M | -$116K | $3.1M | |
| Free Cash Flow | -$9.6M | -$9.8M | -$9.8M | -$1.8M | -$2.1M | |
BHST
Sector
Market Cap
$119.7M
$249.4M
Price % of 52-Week High
87.91%
75%
Dividend Yield
0%
0%
Shareholder Yield
--
2.89%
1-Year Price Total Return
16.51%
-10.33%
Beta (5-Year)
1.222
0.377
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$7.1327
200-day SMA
Buy
Level
$5.9732
Bollinger Bands (100)
Buy
Level
5.6959 - 6.9559
Chaikin Money Flow
Sell
Level
-74.2K
20-day SMA
Sell
Level
$6.9667
Relative Strength Index (RSI14)
Sell
Level
48.8740
ADX Line
Buy
Level
23.0632
Williams %R
Neutral
Level
-55.0875
50-day SMA
Buy
Level
$6.7744
MACD (12, 26)
Buy
Level
0.0852
25-day Aroon Oscillator
Sell
Level
-32
On Balance Volume
Neutral
Level
413.1K
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-3.0627)
Sell
CA Score
(Annual)
Level (-5.6587)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (5)
Sell
Ohlson Score
Level (7.7794)
Buy
Piotroski F Score
(Annual)
Level (7)
Buy
Quality Ratio Score
Level (8)
Sell
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
BioHarvest Sciences Inc is the developer and owner of the patented bio-cell growth platform farming technology. This company is the industrial large-scale plant cell growth technology capable of directly and constantly producing active plant ingredients without the necessity to grow the plant itself. The company is focused on leveraging its botanical synthesis technology to develop the next generation of science-based and clinical therapeutic solutions, within two business verticals - nutraceutical health and wellness products such as dietary supplements, and the development of plant cell-based Active Pharmaceutical Ingredients (APIs) that focus on specific medical indications.
Stock Forecast FAQ
In the current month, BHST has received 1 Buy ratings 0 Hold ratings, and 0 Sell ratings. The BHST average analyst price target in the past 3 months is $14.7500.
-
Where Will BioHarvest Sciences Stock Be In 1 Year?
According to analysts, the consensus estimate is that BioHarvest Sciences share price will rise to $14.7500 per share over the next 12 months.
-
What Do Analysts Say About BioHarvest Sciences?
Analysts are divided on their view about BioHarvest Sciences share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that BioHarvest Sciences is a Sell and believe this share price will drop from its current level to $12.0000.
-
What Is BioHarvest Sciences's Price Target?
The price target for BioHarvest Sciences over the next 1-year time period is forecast to be $14.7500 according to 1 Wall Street analyst, 1 of them rates the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is BHST A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for BioHarvest Sciences is a Buy. 1 of 1 analysts rates the stock a Buy at this time.
-
How Can I Buy Shares Of BHST?
You can purchase shares of BioHarvest Sciences via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase BioHarvest Sciences shares.
-
What Is The BioHarvest Sciences Share Price Today?
BioHarvest Sciences was last trading at $7.0500 per share. This represents the most recent stock quote for BioHarvest Sciences. Yesterday, BioHarvest Sciences closed at $6.9093 per share.
-
How To Buy BioHarvest Sciences Stock Online?
In order to purchase BioHarvest Sciences stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will FCX Benefit From Tariffs?
Freeport-McMoRan (NYSE:FCX) is among the world’s largest producers of copper…
Can Levi Stock Double?
Levi Strauss (NYSE:LEVI) is among the oldest clothing brands in…
Stock Ideas
Buy
71
Is NVDA Stock a Buy?
Market Cap: $4.2T
P/E Ratio: 59x
Buy
51
Is MSFT Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 43x
Sell
40
Is AAPL Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 35x
Alerts
Buy
68
MCRI alert for Jul 18
Monarch Casino & Resort [MCRI] is up 19.81% over the past day.
Sell
41
NEGG alert for Jul 18
Newegg Commerce [NEGG] is up 17.85% over the past day.
Buy
72
MNPR alert for Jul 18
Monopar Therapeutics [MNPR] is up 13.2% over the past day.
